A Clinical Study to Evaluate the Safety and Pharmacokinetics of JNJ- 73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or in Combinations With JNJ-61186372, a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non-Small Cell Lung Cancer

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-506577-35-00

Acronym

73841937NSC1001

Enrollment

209

Registered

2024-03-13

Start date

2020-09-08

Completion date

Unknown

Last updated

2025-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced Non-Small Cell Lung Cancer

None listed

Sex/Gender

All

Age

18 Years to No maximum

France, Germany, Italy, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026